JP2018515506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515506A5 JP2018515506A5 JP2017558372A JP2017558372A JP2018515506A5 JP 2018515506 A5 JP2018515506 A5 JP 2018515506A5 JP 2017558372 A JP2017558372 A JP 2017558372A JP 2017558372 A JP2017558372 A JP 2017558372A JP 2018515506 A5 JP2018515506 A5 JP 2018515506A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- disease
- disorder
- calcium
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 206010012289 Dementia Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 229910052791 calcium Inorganic materials 0.000 claims 3
- 239000011575 calcium Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000008188 pellet Substances 0.000 claims 3
- 238000013268 sustained release Methods 0.000 claims 3
- 239000012730 sustained-release form Substances 0.000 claims 3
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 208000001914 Fragile X syndrome Diseases 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 229960001157 acamprosate calcium Drugs 0.000 claims 2
- BUVGWDNTAWHSKI-UHFFFAOYSA-L acamprosate calcium Chemical compound [Ca+2].CC(=O)NCCCS([O-])(=O)=O.CC(=O)NCCCS([O-])(=O)=O BUVGWDNTAWHSKI-UHFFFAOYSA-L 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 230000004641 brain development Effects 0.000 claims 1
- 229920003086 cellulose ether Polymers 0.000 claims 1
- 208000024825 childhood disintegrative disease Diseases 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000030251 communication disease Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 230000013016 learning Effects 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000015654 memory Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003274 myotonic effect Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 238000003892 spreading Methods 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 229920001169 thermoplastic Polymers 0.000 claims 1
- 239000004416 thermosoftening plastic Substances 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021103349A JP2021155434A (ja) | 2015-05-04 | 2021-06-22 | アカンプロサートのスプリンクル製剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156842P | 2015-05-04 | 2015-05-04 | |
| US62/156,842 | 2015-05-04 | ||
| US201562260161P | 2015-11-25 | 2015-11-25 | |
| US62/260,161 | 2015-11-25 | ||
| PCT/US2016/030725 WO2016179252A1 (en) | 2015-05-04 | 2016-05-04 | Sprinkle formulations of acamprosate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103349A Division JP2021155434A (ja) | 2015-05-04 | 2021-06-22 | アカンプロサートのスプリンクル製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515506A JP2018515506A (ja) | 2018-06-14 |
| JP2018515506A5 true JP2018515506A5 (https=) | 2019-06-06 |
| JP7026347B2 JP7026347B2 (ja) | 2022-02-28 |
Family
ID=57217823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017558372A Active JP7026347B2 (ja) | 2015-05-04 | 2016-05-04 | アカンプロサートのスプリンクル製剤 |
| JP2021103349A Pending JP2021155434A (ja) | 2015-05-04 | 2021-06-22 | アカンプロサートのスプリンクル製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103349A Pending JP2021155434A (ja) | 2015-05-04 | 2021-06-22 | アカンプロサートのスプリンクル製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10709668B2 (https=) |
| EP (1) | EP3291800A4 (https=) |
| JP (2) | JP7026347B2 (https=) |
| KR (1) | KR102790656B1 (https=) |
| AU (1) | AU2016258624B2 (https=) |
| HK (1) | HK1252003A1 (https=) |
| IL (1) | IL255343B2 (https=) |
| SG (1) | SG11201708393UA (https=) |
| WO (1) | WO2016179252A1 (https=) |
| ZA (1) | ZA201708037B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10357469B2 (en) | 2015-02-18 | 2019-07-23 | Aston University | Diagnostic assay and treatment for preeclampsia |
| SG11201708393UA (en) | 2015-05-04 | 2017-11-29 | Confluence Pharmaceuticals Llc | Sprinkle formulations of acamprosate |
| HK1255584A1 (zh) * | 2015-08-04 | 2019-08-23 | Confluence Pharmaceuticals, Llc | 使用阿坎酸及d-环丝胺酸的联合疗法 |
| IL270654B2 (en) * | 2017-05-17 | 2024-07-01 | Confluence Pharmaceuticals Llc | Formulations of homotaurines and salts thereof |
| ES2938609T3 (es) * | 2017-09-20 | 2023-04-13 | Tillotts Pharma Ag | Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión |
| EP4213817A1 (en) * | 2020-09-21 | 2023-07-26 | Sun Pharmaceutical Industries Limited | Multi-particulate pharmaceutical composition of quetiapine |
| EP4406479A4 (en) | 2021-09-24 | 2025-05-07 | Sumitomo Bakelite Co.Ltd. | Brain wave detection electrode, brain wave measurement device, and brain wave measurement method |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514530B2 (en) | 1997-09-09 | 2003-02-04 | Alza Corporation | Dosage form comprising means for changing drug delivery shape |
| DE1073432T1 (de) | 1998-04-14 | 2002-02-07 | The General Hospital Corp., Boston | Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden |
| US20050042277A1 (en) * | 2003-07-17 | 2005-02-24 | Irukulla Srinivas | Pharmaceutical compositions having a swellable coating |
| DE102007009243A1 (de) | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
| JP2010532331A (ja) | 2007-07-05 | 2010-10-07 | アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） | 抗痙攣医薬組成物 |
| CA2781830C (en) | 2009-02-12 | 2018-03-27 | Indiana University Research & Technology Corporation | Materials and methods for treating developmental disorders including comorbid and idiopathic autism |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20110142889A1 (en) | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| MX346203B (es) * | 2010-09-28 | 2017-03-09 | Depomed Inc | Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior. |
| TR201809351T4 (tr) | 2011-03-01 | 2018-07-23 | Pharnext | Nörolojik bozuklukların baklofen ve akamprosat tabanlı terapisi. |
| DK3272342T3 (da) * | 2011-03-23 | 2021-06-07 | Ironshore Pharmaceuticals & Dev Inc | Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse |
| JP5893135B2 (ja) | 2011-06-28 | 2016-03-23 | ビボゾーン インコーポレイテッド | 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途 |
| US20130143867A1 (en) * | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| WO2014197744A1 (en) * | 2013-06-05 | 2014-12-11 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| AU2015217796B2 (en) | 2014-02-11 | 2020-04-30 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
| SG11201708393UA (en) | 2015-05-04 | 2017-11-29 | Confluence Pharmaceuticals Llc | Sprinkle formulations of acamprosate |
-
2016
- 2016-05-04 SG SG11201708393UA patent/SG11201708393UA/en unknown
- 2016-05-04 KR KR1020177033137A patent/KR102790656B1/ko active Active
- 2016-05-04 IL IL255343A patent/IL255343B2/en unknown
- 2016-05-04 EP EP16789996.2A patent/EP3291800A4/en active Pending
- 2016-05-04 WO PCT/US2016/030725 patent/WO2016179252A1/en not_active Ceased
- 2016-05-04 HK HK18111332.4A patent/HK1252003A1/zh unknown
- 2016-05-04 AU AU2016258624A patent/AU2016258624B2/en active Active
- 2016-05-04 JP JP2017558372A patent/JP7026347B2/ja active Active
- 2016-05-04 US US15/569,937 patent/US10709668B2/en active Active
-
2017
- 2017-11-27 ZA ZA2017/08037A patent/ZA201708037B/en unknown
-
2021
- 2021-06-22 JP JP2021103349A patent/JP2021155434A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515506A5 (https=) | ||
| IL255782A (en) | Extended release pharmaceutical compositions of levetiracetam | |
| Ling et al. | All-carbon quaternary centers in natural products and medicinal chemistry: recent advances | |
| JP2011063627A5 (https=) | ||
| King et al. | Glycogen synthase kinase-3 inhibitors: rescuers of cognitive impairments | |
| JP2020023518A5 (https=) | ||
| CA2936746C (en) | Methods and compositions particularly for treatment of attention deficit disorder | |
| JP2018516906A5 (https=) | ||
| CN115521217A (zh) | 神经衰减性氯胺酮和去甲氯胺酮化合物、其衍生物和方法 | |
| MX2021005106A (es) | Esteroides neuroactivos, composiciones, y usos de los mismos. | |
| JP2017536407A5 (https=) | ||
| FI3702351T3 (fi) | MEK-inhibiittorin käsittävä koostumus | |
| WO2016065226A8 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| NZ591873A (en) | Co-crystals of tramadol and nsaids | |
| Zhang et al. | Research progress of preparation technology of ion-exchange resin complexes | |
| JP2017505811A5 (https=) | ||
| TW200738228A (en) | Neramexane modified release matrix tablet | |
| JP2014516535A5 (https=) | ||
| JP2018526345A5 (https=) | ||
| WO2008120070A3 (en) | 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) displaying hepatoprotective, hypoammoniemic and detoxic action, a method for its production and a pharmaceutical composition based thereon | |
| HRP20220856T1 (hr) | Pripravci ugodna okusa uključujući natrijev fenilbutirat i njihove uporabe | |
| JP2019513814A5 (https=) | ||
| CN106265601A (zh) | 一种布洛芬缓释制剂及其制备方法 | |
| CN103816135B (zh) | 盐酸美金刚缓释制剂及其制备方法 | |
| JP2015120758A5 (https=) |